First Hospital of Shijiazhuang City   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 4
Founded: Shijiazhuang China (1938)

Organization Overview

First Clinical Trial
2014
NCT02280850
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

First Hospital of Shijiazhuang City | The First Hospital of Shijiazhuang

Active Ingredients

Drugs in Phase 4 Trials (3)

Andrographis paniculata (1 trial)

guanxin shutong (1 trial)

nitroglycerin (transderm-nitro) (1 trial)

Drugs in Phase 2 Trials (2)

anlotinib (2 trials)

sintilimab (1 trial)

Drugs in Phase 1 Trials (1)

personalized neoantigen vaccine (1 trial)

Drugs in Other Trials (2)

midazolam (versed) (1 trial)

remimazolam (Byfavo) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 4)

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Bronchitis (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 8